

David R Coghill

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8625763/david-r-coghill-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

193
papers

10,291
citations

57
h-index

97
g-index

225
ext. papers

13,089
ext. citations

6.1
avg, IF

6.27
L-index

#	Paper	IF	Citations
193	How can the education sector support children's mental health? Views of Australian healthcare clinicians.. <i>PLoS ONE</i> , 2022 , 17, e0261827	3.7	
192	Examining the Educational Gap for Children with ADHD and Subthreshold ADHD. <i>Journal of Attention Disorders</i> , 2022 , 26, 282-295	3.7	4
191	Social and Economic Costs of Attention-Deficit/Hyperactivity Disorder Across the Lifespan. <i>Journal of Attention Disorders</i> , 2022 , 26, 72-87	3.7	8
190	A rapid systematic review of attention-deficit/hyperactivity disorder (ADHD) and high order writing: Current findings and implications for intervention.. <i>Research in Developmental Disabilities</i> , 2022 , 123, 104180	2.7	1
189	What Is the Health and Well-Being Burden for Parents Living With a Child With ADHD in the United Kingdom?. <i>Journal of Attention Disorders</i> , 2021 , 25, 1962-1976	3.7	4
188	The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG). <i>European Child and Adolescent Psychiatry</i> , 2021 , 1	5.5	5
187	Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2021 , 1-12	6.9	3
186	Characterizing neuroanatomic heterogeneity in people with and without ADHD based on subcortical brain volumes. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2021 , 62, 1140-1149 ³	7.9	11
185	Attention Deficit Hyperactivity Disorder in Males 2021 , 25-42		
184	Analysis of structural brain asymmetries in attention-deficit/hyperactivity disorder in 39 datasets. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2021 , 62, 1202-1219	7.9	7
183	A Longitudinal Study of the Relation between Childhood Activities and Psychosocial Adjustment in Early Adolescence. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	5
182	Treatment with Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) and the Risk of All-Cause Poisoning in Children and Adolescents: A Self-Controlled Case Series Study. <i>CNS Drugs</i> , 2021 , 35, 769-779	6.7	0
181	Association between methylphenidate and risk of myocardial infarction: A multinational self-controlled case series study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 1458-1467	2.6	0
180	Functional impairment outcomes in clinical trials of different ADHD medications: post hoc responder analyses and baseline subgroup analyses. <i>European Child and Adolescent Psychiatry</i> , 2021 , 30, 809-821	5.5	2
179	Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 , 120, 509-525	9	11
178	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. <i>JAMA Psychiatry</i> , 2021 , 78, 47-63	14.5	43
177	Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1. <i>Journal of Attention Disorders</i> , 2021 , 25, 1177-1186	3.7	16

176	Clinicians' Perceptions of the Australian Paediatric Mental Health Service System: Problems and solutions. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021 , 55, 494-505	2.6	6
175	A novel school-based approach to screening for attention deficit hyperactivity disorder. <i>European Child and Adolescent Psychiatry</i> , 2021 , 1	5.5	1
174	Disentangling ADHD's Presentation-Related Decision-Making-A Meta-Analytic Approach on Predominant Presentations. <i>Frontiers in Psychiatry</i> , 2021 , 12, 519840	5	1
173	Effects of methylphenidate on cognitive functions in boys with attention deficit hyperactivity disorder: Does baseline performance matter?. <i>Journal of Consulting and Clinical Psychology</i> , 2021 , 89, 615-625	6.5	1
172	The Monash Autism-ADHD genetics and neurodevelopment (MAGNET) project design and methodologies: a dimensional approach to understanding neurobiological and genetic aetiology. <i>Molecular Autism</i> , 2021 , 12, 55	6.5	
171	A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD). <i>CNS Drugs</i> , 2021 , 35, 1035-1051	6.7	3
170	Association Between Prenatal Exposure to Antipsychotics and Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Preterm Birth, and Small for Gestational Age. <i>JAMA Internal Medicine</i> , 2021 , 181, 1332-1340	11.5	5
169	Suicidality and Self-harm in Adolescents With Attention-Deficit/Hyperactivity Disorder and Subsyndromal ADHD. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021 , 60, 1049-1051	7.2	13
168	The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 , 128, 789-818	9	92
167	A systematic review of the persistence of childhood mental health problems into adulthood. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 , 129, 182-205	9	2
166	Psychostimulants: Primary and Secondary Indications 2021 , 1-13		
165	Consortium neuroscience of attention deficit/hyperactivity disorder and autism spectrum disorder: The ENIGMA adventure. <i>Human Brain Mapping</i> , 2020 ,	5.9	17
164	Starting ADHD medications during the COVID-19 pandemic: recommendations from the European ADHD Guidelines Group. <i>The Lancet Child and Adolescent Health</i> , 2020 , 4, e15	14.5	16
163	Psychotropic Drug Treatment in Childhood and Adolescence 2020 , 525-542		
162	The value of early intervention in creating the new mental health system: Response to Allison et al. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020 , 54, 667-669	2.6	4
161	Association between methylphenidate treatment and risk of seizure: a population-based, self-controlled case-series study. <i>The Lancet Child and Adolescent Health</i> , 2020 , 4, 435-443	14.5	13
160	Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2020 , 7, 581-601	23.3	58
159	Evaluation of causality between ADHD and Parkinson's disease: Mendelian randomization study. <i>European Neuropsychopharmacology</i> , 2020 , 37, 49-63	1.2	3

158	Subcortical Brain Volume, Regional Cortical Thickness, and Cortical Surface Area Across Disorders: Findings From the ENIGMA ADHD, ASD, and OCD Working Groups. <i>American Journal of Psychiatry</i> , 2020 , 177, 834-843	11.9	50
157	Post hoc analyses of response rates to pharmacological treatments in children and adolescents with attention-deficit/hyperactivity disorder. <i>Journal of Psychopharmacology</i> , 2020 , 34, 874-882	4.6	0
156	Physical exercise in attention deficit hyperactivity disorder - evidence and implications for the treatment of borderline personality disorder. <i>Borderline Personality Disorder and Emotion Dysregulation</i> , 2020 , 7, 1	4.9	14
155	ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group. <i>The Lancet Child and Adolescent Health</i> , 2020 , 4, 412-414	14.5	95
154	Pharmacological Approaches in Child and Adolescent Mental Health. <i>Mental Health and Illness Worldwide</i> , 2020 , 1-31	0.1	
153	Developmental perspectives on ADHD, treatment implications, and achieving good outcomes 2020 , 211-236		
152	Is minimally adequate treatment really adequate? investigating the effect of mental health treatment on quality of life for children with mental health problems. <i>Journal of Affective Disorders</i> , 2020 , 276, 327-334	6.6	1
151	Pharmacological Approaches in Child and Adolescent Mental Health. <i>Mental Health and Illness Worldwide</i> , 2020 , 543-573	0.1	1
150	Physical Health, Media Use, and Mental Health in Children and Adolescents With ADHD During the COVID-19 Pandemic in Australia. <i>Journal of Attention Disorders</i> , 2020 , 1087054720978549	3.7	37
149	Psychosocial risk factors for suicidality in children and adolescents. <i>European Child and Adolescent Psychiatry</i> , 2020 , 29, 759-776	5.5	76
148	Use and predictors of health services among Australian children with mental health problems: A national prospective study. <i>Australian Journal of Psychology</i> , 2020 , 72, 31-40	2.3	8
147	Mental health difficulties across childhood and mental health service use: findings from a longitudinal population-based study. <i>British Journal of Psychiatry</i> , 2020 , 217, 364-369	5.4	5
146	Patterns of long-term ADHD medication use in Australian children. <i>Archives of Disease in Childhood</i> , 2020 , 105, 593-597	2.2	10
145	Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence. <i>Neuroscience and Biobehavioral Reviews</i> , 2019 , 107, 945-968	9	27
144	Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder-outcome measures beyond symptom control and clinical trials. <i>Lancet Psychiatry</i> , 2019 , 6, 528-537	23.3	21
143	Brain Imaging of the Cortex in ADHD: A Coordinated Analysis of Large-Scale Clinical and Population-Based Samples. <i>American Journal of Psychiatry</i> , 2019 , 176, 531-542	11.9	120
142	Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019 , 29, 285-304	2.9	1
141	Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. <i>Molecular Psychiatry</i> , 2019 , 24, 390-408	15.1	59

140	Reply to Leon. <i>Evidence-Based Mental Health</i> , 2019 , 22, e2	11.1	1
139	Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 2555-2565	5.3	11
138	The Age of Onset of Attention-Deficit Hyperactivity Disorder 2019 , 217-236		2
137	Validity and reliability of the Dundee difficult times of the day scale in Chinese children and adolescents with attention-deficit/hyperactivity disorder. <i>Journal of Comparative Effectiveness Research</i> , 2019 , 8, 33-44	2.1	1
136	Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD. <i>Journal of Attention Disorders</i> , 2019 , 23, 1578-1591	3.7	9
135	Polyunsaturated fatty acids metabolism, purine metabolism and inosine as potential independent diagnostic biomarkers for major depressive disorder in children and adolescents. <i>Molecular Psychiatry</i> , 2019 , 24, 1478-1488	15.1	57
134	ADHD Symptoms and Quality of Life Across a 12-Month Period in Children With ADHD: A Longitudinal Study. <i>Journal of Attention Disorders</i> , 2019 , 23, 1675-1685	3.7	10
133	An international clinical study of ability and disability in ADHD using the WHO-ICF framework. <i>European Child and Adolescent Psychiatry</i> , 2018 , 27, 1305-1319	5.5	7
132	Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate. <i>CNS Drugs</i> , 2018 , 32, 85-95	6.7	13
131	Standardised assessment of functioning in ADHD: consensus on the ICF Core Sets for ADHD. <i>European Child and Adolescent Psychiatry</i> , 2018 , 27, 1261-1281	5.5	22
130	Prenatal antidepressant exposure and the risk of attention-deficit hyperactivity disorder in children: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2018 , 86, 1-11	9	18
129	Barriers to medication entitlements after diagnosis of ADHD - AuthorsReply. <i>Lancet Psychiatry</i> , 2018 , 5, 19-20	23.3	
128	The pharmacological treatment of aggression in children and adolescents with conduct disorder. Do callous-unemotional traits modulate the efficacy of medication?. <i>Neuroscience and Biobehavioral Reviews</i> , 2018 , 91, 218-238	9	20
127	A comparison of the clinical effectiveness and cost of specialised individually delivered parent training for preschool attention-deficit/hyperactivity disorder and a generic, group-based programme: a multi-centre, randomised controlled trial of the New Forest Parenting Programme versus Incredible Years. <i>European Child and Adolescent Psychiatry</i> , 2018 , 27, 797-809	5.5	20
126	ADHD in children and young people: prevalence, care pathways, and service provision. <i>Lancet Psychiatry</i> , 2018 , 5, 175-186	23.3	280
125	Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2018 , 59, 932-947	7.9	78
124	Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2018 , 5, 727-738	23.3	378
123	Developing the Symptoms and Functional Impairment Rating Scale: A Multi-Dimensional ADHD Scale. <i>Psychiatry Investigation</i> , 2018 , 15, 13-23	3.1	4

122	Unbalanced risk-benefit analysis of ADHD drugs - AuthorsSreply. <i>Lancet Psychiatry,the</i> , 2018 , 5, 871-873	23.3	2
121	Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward. <i>Evidence-Based Mental Health</i> , 2018 , 21, 173-176	11.1	44
120	Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). <i>BMC Psychiatry</i> , 2018 , 18, 327	4.2	8
119	Can depression be prevented in children and adolescents?. <i>Journal of Paediatrics and Child Health</i> , 2018 , 54, 1386-1388	1.3	
118	Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. <i>Lancet Psychiatry,the</i> , 2018 , 5, 824-835	23.3	105
117	Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial. <i>BMJ Open</i> , 2018 , 8, e021800	3	7
116	Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>CNS Drugs</i> , 2018 , 32, 455-467	6.7	9
115	Mapping cortical brain asymmetry in 17,141 healthy individuals worldwide via the ENIGMA Consortium. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E5154-E5163	11.5	182
114	Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis. <i>BMJ Open</i> , 2017 , 7, e013967	3	20
113	Prenatal Risk Factors and the Etiology of ADHD-Review of Existing Evidence. <i>Current Psychiatry Reports</i> , 2017 , 19, 1	9.1	113
112	Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. <i>CNS Drugs</i> , 2017 , 31, 199-215	6.7	94
111	Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. <i>European Child and Adolescent Psychiatry</i> , 2017 , 26, 1283-1307	5.5	40
110	A conceptual framework for a long-term economic model for the treatment of attention-deficit/hyperactivity disorder. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017 , 17, 283-292	2.2	1
109	Association of Risk of Suicide Attempts With Methylphenidate Treatment. <i>JAMA Psychiatry</i> , 2017 , 74, 1048-1055	14.5	64
108	Comparative efficacy and acceptability of antidepressants, psychological interventions, and their combination for depressive disorder in children and adolescents: protocol for a network meta-analysis. <i>BMJ Open</i> , 2017 , 7, e016608	3	11
107	Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe. <i>CNS Drugs</i> , 2017 , 31, 625-638	6.7	25
106	Annual Research Review: Quality of life and childhood mental and behavioural disorders - a critical review of the research. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2017 , 58, 439-469	7.9	79
105	Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. <i>BMJ, The</i> , 2017 , 357, j2350	5.9	62

104	Personalized Medication Response Prediction for Attention-Deficit Hyperactivity Disorder: Learning in the Model Space vs. Learning in the Data Space. <i>Frontiers in Physiology</i> , 2017 , 8, 199	4.6	8
103	The European ADHD Guidelines Group replies. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016 , 55, 1092-1093	7.2	2
102	Recommendations for the transition of patients with ADHD from child to adult healthcare services: a consensus statement from the UK adult ADHD network. <i>BMC Psychiatry</i> , 2016 , 16, 301	4.2	33
101	Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. <i>Lancet, The</i> , 2016 , 388, 881-90	4.0	343
100	Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database. <i>CNS Drugs</i> , 2016 , 30, 317-34	6.7	1
99	The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research. <i>CNS Drugs</i> , 2016 , 30, 603-28	6.7	33
98	Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2016 , 30, 495-553	4.6	468
97	Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016 , 26, 537-47	2.9	12
96	Health-related quality of life of children with attention-deficit/hyperactivity disorder versus children with diabetes and healthy controls. <i>European Child and Adolescent Psychiatry</i> , 2016 , 25, 261-71	5.5	41
95	Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate. <i>European Child and Adolescent Psychiatry</i> , 2016 , 25, 111-9	5.5	14
94	Relationships between behavioral symptoms of non-medicated Chinese children with attention deficit hyperactivity disorder and parenting stress: Comparison of different subtypes and comorbidities. <i>Asia-Pacific Psychiatry</i> , 2016 , 8, 127-35	3.2	6
93	Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater. <i>Evidence-Based Mental Health</i> , 2016 , 19, 97-99	11.1	20
92	Neurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016 , 55, 444-55	7.2	150
91	The impact of ADHD on the health and well-being of ADHD children and their siblings. <i>European Child and Adolescent Psychiatry</i> , 2016 , 25, 1217-1231	5.5	57
90	The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research. <i>CNS Drugs</i> , 2015 , 29, 131-51	6.7	28
89	Pharmacological treatment of attention-deficit/hyperactivity disorder: assessing outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2015 , 8, 383-97	3.8	15
88	Ability and Disability in Autism Spectrum Disorder: A Systematic Literature Review Employing the International Classification of Functioning, Disability and Health-Children and Youth Version. <i>Autism Research</i> , 2015 , 8, 782-94	5.1	48
87	Towards an ICF core set for ADHD: a worldwide expert survey on ability and disability. <i>European Child and Adolescent Psychiatry</i> , 2015 , 24, 1509-21	5.5	22

86	A comprehensive scoping review of ability and disability in ADHD using the International Classification of Functioning, Disability and Health-Children and Youth Version (ICF-CY). <i>European Child and Adolescent Psychiatry</i> , 2015 , 24, 859-72	5.5	27
85	Predicting methylphenidate response in attention deficit hyperactivity disorder: a preliminary study. <i>Journal of Psychopharmacology</i> , 2015 , 29, 24-30	4.6	27
84	Commentary: We've only just begun: unravelling the underlying genetics of neurodevelopmental disorders--a commentary on Kiser et al. (2015). <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2015 , 56, 296-8	7.9	2
83	Group cognitive-behavioural therapy may reduce symptoms and impairment in adolescents with attention-deficit/hyperactivity disorder. <i>Evidence-Based Mental Health</i> , 2015 , 18, 125	11.1	1
82	Services for adults with ADHD: work in progress: Commentary on . . . Specialist adult ADHD clinics in East Anglia. <i>BJPsych Bulletin</i> , 2015 , 39, 140-3	1.2	10
81	Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD Clinical Care Pathway. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2015 , 9, 52	6.8	45
80	Methylphenidate and the risk of trauma. <i>Pediatrics</i> , 2015 , 135, 40-8	7.4	75
79	The use of stimulant medications for non-core aspects of ADHD and in other disorders. <i>Neuropharmacology</i> , 2014 , 87, 161-72	5.5	25
78	Brainstem abnormalities in attention deficit hyperactivity disorder support high accuracy individual diagnostic classification. <i>Human Brain Mapping</i> , 2014 , 35, 5179-89	5.9	58
77	A systematic review of the safety of lisdexamfetamine dimesylate. <i>CNS Drugs</i> , 2014 , 28, 497-511	6.7	53
76	Study protocol for a randomized controlled trial comparing the efficacy of a specialist and a generic parenting programme for the treatment of preschool ADHD. <i>Trials</i> , 2014 , 15, 142	2.8	9
75	Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2014 , 28, 179-203	4.6	191
74	Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014 , 53, 647-657.e1	7.2	35
73	Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial. <i>Neuropsychiatric Disease and Treatment</i> , 2014 , 10, 2039-47	3.1	14
72	Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. <i>CNS Drugs</i> , 2014 , 28, 1059-69	6.7	21
71	Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. <i>CNS Drugs</i> , 2014 , 28, 1191-203	6.7	31
70	A comprehensive assessment of memory, delay aversion, timing, inhibition, decision making and variability in attention deficit hyperactivity disorder: advancing beyond the three-pathway models. <i>Psychological Medicine</i> , 2014 , 44, 1989-2001	6.9	130
69	A longitudinal examination of neuropsychological and clinical functioning in boys with attention deficit hyperactivity disorder (ADHD): improvements in executive functioning do not explain clinical improvement. <i>Psychological Medicine</i> , 2014 , 44, 1087-99	6.9	104

68	Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. <i>Biological Psychiatry</i> , 2014 , 76, 603-15	7.9	169
67	Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial. <i>European Child and Adolescent Psychiatry</i> , 2014 , 23, 61-8	5.5	25
66	Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. <i>European Child and Adolescent Psychiatry</i> , 2014 , 23, 1149-60	5.5	13
65	Occupational issues of adults with ADHD. <i>BMC Psychiatry</i> , 2013 , 13, 59	4.2	52
64	Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. <i>CNS Drugs</i> , 2013 , 27, 829-40	6.7	45
63	A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents. <i>CNS Drugs</i> , 2013 , 27, 743-51	6.7	31
62	An inventory of European data sources for the long-term safety evaluation of methylphenidate. <i>European Child and Adolescent Psychiatry</i> , 2013 , 22, 605-18	5.5	14
61	Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. <i>BMC Psychiatry</i> , 2013 , 13, 237	4.2	59
60	The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). <i>Child and Adolescent Psychiatry and Mental Health</i> , 2013 , 7, 34	6.8	48
59	Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. <i>CNS Drugs</i> , 2013 , 27, 1081-92	6.7	64
58	European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. <i>European Neuropsychopharmacology</i> , 2013 , 23, 1208-18	1.2	87
57	Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2013 , 54, 227-46	7.9	190
56	Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. <i>American Journal of Psychiatry</i> , 2013 , 170, 275-89	11.9	697
55	Non-stimulant Drug Treatments for Adults with ADHD 2013 , 89-117		1
54	Amphetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. <i>European Child and Adolescent Psychiatry</i> , 2012 , 21, 477-92	5.5	81
53	A comprehensive investigation of memory impairment in attention deficit hyperactivity disorder and oppositional defiant disorder. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2012 , 53, 128-37	7.9	68
52	Commentary response: Addressing the challenges [response to the commentary of Jarrold and Hall (2012)]. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2012 , 53, 141-142	7.9	
51	Annual research review: categories versus dimensions in the classification and conceptualisation of child and adolescent mental disorders—implications of recent empirical study. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2012 , 53, 469-89	7.9	200

50	Pragmatic measures in paediatric psychopharmacology--are we getting it right?. <i>European Neuropsychopharmacology</i> , 2011 , 21, 571-83	1.2	14
49	European guidelines on managing adverse effects of medication for ADHD. <i>European Child and Adolescent Psychiatry</i> , 2011 , 20, 17-37	5.5	244
48	Do the diagnostic criteria for ADHD need to change? Comments on the preliminary proposals of the DSM-5 ADHD and Disruptive Behavior Disorders Committee. <i>European Child and Adolescent Psychiatry</i> , 2011 , 20, 75-81	5.5	32
47	Avoiding the twilight zone's recommendations for the transition of services from adolescence to adulthood for young people with ADHD. <i>BMC Psychiatry</i> , 2011 , 11, 174	4.2	68
46	Escalas y cuestionarios pragmáticos en psicofarmacología pediátrica: ¿estamos haciendo lo correcto?. <i>Psiquiatria Biologica</i> , 2011 , 18, 105-116	0.2	
45	Attention-deficit/hyperactivity disorder and Williams syndrome: shared behavioral and neuropsychological profiles. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2011 , 33, 147-56	2.1	48
44	Pharmacotherapy for Children and Adolescents with Conduct Problems 2011 , 383-404		1
43	Short-term effectiveness of medication and psychosocial intervention in a cohort of newly diagnosed patients with inattention, impulsivity, and hyperactivity problems. <i>Journal of Attention Disorders</i> , 2010 , 14, 147-56	3.7	8
42	Neurofeedback training improves ADHD symptoms more than attention skills training. <i>Evidence-Based Mental Health</i> , 2010 , 13, 21	11.1	1
41	The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. <i>CNS Drugs</i> , 2010 , 24, 843-66	6.7	64
40	Stimulant drug effects on attention deficit/hyperactivity disorder: a review of the effects of age and sex of patients. <i>Current Pharmaceutical Design</i> , 2010 , 16, 2424-33	3.3	27
39	The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. <i>European Child and Adolescent Psychiatry</i> , 2010 , 19, 83-105	5.5	298
38	Molecular genetics of attention-deficit/hyperactivity disorder: an overview. <i>European Child and Adolescent Psychiatry</i> , 2010 , 19, 237-57	5.5	170
37	Eunethydis: a statement of the ethical principles governing the relationship between the European group for ADHD guidelines, and its members, with commercial for-profit organisations. <i>European Child and Adolescent Psychiatry</i> , 2010 , 19, 737-9	5.5	2
36	Measuring methylphenidate response in attention-deficit/hyperactivity disorder: how are laboratory classroom-based measures related to parent ratings?. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009 , 19, 691-8	2.9	13
35	Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. <i>British Journal of Psychiatry</i> , 2009 , 194, 273-7	5.4	148
34	Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009 , 19, 683-90	2.9	49
33	The genetics of attention-deficit/hyperactivity disorder. <i>Expert Review of Neurotherapeutics</i> , 2009 , 9, 1547-65	4.3	49

32	Practitioner review: Quality of life in child mental health--conceptual challenges and practical choices. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2009 , 50, 544-61	7.9	92
31	Replication of an association of a promoter polymorphism of the dopamine transporter gene and Attention Deficit Hyperactivity Disorder. <i>Neuroscience Letters</i> , 2009 , 462, 179-81	3.3	13
30	The MTA at 8. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009 , 48, 1120-1122	7.2	18
29	OSH Child and Adolescent Psychiatry 2009 ,		10
28	Neuropsychological functioning in depressed adolescent girls. <i>Journal of Affective Disorders</i> , 2008 , 111, 113-8	6.6	60
27	Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. <i>CNS Drugs</i> , 2008 , 22, 213-37	6.7	127
26	The provision and nature of ADHD services for children/adolescents in the UK: results from a nationwide survey. <i>Clinical Child Psychology and Psychiatry</i> , 2008 , 13, 287-304	2	7
25	Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. <i>Pediatrics</i> , 2008 , 121, e314-20	7.4	64
24	Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder. A growth mixture modelling analysis. <i>European Child and Adolescent Psychiatry</i> , 2008 , 17, 245-54	5.5	19
23	Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2008 , 2, 31	6.8	86
22	The validity, reliability and normative scores of the parent, teacher and self report versions of the Strengths and Difficulties Questionnaire in China. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2008 , 2, 8	6.8	185
21	Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007 , 46, 701-710	7.2	43
20	The neuropsychological effects of chronic methylphenidate on drug-naïve boys with attention-deficit/hyperactivity disorder. <i>Biological Psychiatry</i> , 2007 , 62, 954-62	7.9	124
19	Adding multimodal behavioural therapy to methylphenidate does not improve ADHD outcomes. <i>Evidence-Based Mental Health</i> , 2007 , 10, 124	11.1	3
18	Osmotic, controlled-release methylphenidate for the treatment of ADHD. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 2119-38	4	26
17	Effect of extended release stimulant-based medications on neuropsychological functioning among adolescents with Attention-Deficit/Hyperactivity Disorder. <i>Archives of Clinical Neuropsychology</i> , 2006 , 21, 797-807	2.7	37
16	Acute neuropsychological effects of methylphenidate in stimulant drug-naïve boys with ADHD II--broader executive and non-executive domains. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2006 , 47, 1184-94	7.9	83
15	Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. <i>European Child and Adolescent Psychiatry</i> , 2006 , 15, 476-95	5.5	275

14	Study design, baseline patient characteristics and intervention in a cross-cultural framework: results from the ADORE study. <i>European Child and Adolescent Psychiatry</i> , 2006 , 15 Suppl 1, 14-14	5.5	37
13	Which factors impact on clinician-rated impairment in children with ADHD?. <i>European Child and Adolescent Psychiatry</i> , 2006 , 15 Suppl 1, 130-7	5.5	19
12	Factors related to health-related quality of life (HRQoL) among children with ADHD in Europe at entry into treatment. <i>European Child and Adolescent Psychiatry</i> , 2006 , 15 Suppl 1, 138-45	5.5	81
11	Cross-cultural reliability and validity of ADHD assessed by the ADHD Rating Scale in a pan-European study. <i>European Child and Adolescent Psychiatry</i> , 2006 , 15 Suppl 1, 146-55	5.5	72
10	Validity of the health-related quality of life assessment in the ADORE study: Parent Report Form of the CHIP-Child Edition. <i>European Child and Adolescent Psychiatry</i> , 2006 , 15 Suppl 1, 163-71	5.5	50
9	Stimulant treatments for attention deficit/hyperactivity disorder [how safe are they really?]. <i>Evidence-Based Healthcare and Public Health</i> , 2005 , 9, 83-85		
8	Neuropsychological functioning in stimulant-naive boys with hyperkinetic disorder. <i>Psychological Medicine</i> , 2005 , 35, 1109-20	6.9	96
7	Whither causal models in the neuroscience of ADHD?. <i>Developmental Science</i> , 2005 , 8, 105-14	4.5	95
6	Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. <i>BMC Psychiatry</i> , 2004 , 4, 28	4.2	36
5	European clinical guidelines for hyperkinetic disorder -- first upgrade. <i>European Child and Adolescent Psychiatry</i> , 2004 , 13 Suppl 1, 17-30	5.5	316
4	Methylphenidate restores visual memory, but not working memory function in attention deficit-hyperkinetic disorder. <i>Psychopharmacology</i> , 2004 , 175, 319-30	4.7	75
3	Use of stimulants for attention deficit hyperactivity disorder: FOR. <i>BMJ, The</i> , 2004 , 329, 907-8	5.9	19
2	Addressing mental health problems in Australians with cerebral palsy: a need for specialist mental health services. <i>Advances in Mental Health</i> , 1-4	1.2	1
1	Collaborative and Proactive Solutions compared with usual care to treat irritability in children and adolescents: a pilot randomized controlled trial. <i>Clinical Psychologist</i> , 1-9	1.6	